Key result
A dedicated inpatient transitions of care pharmacist reduced 30-day re-presentation rates compared to historical controls.
Why the study?
Does a dedicated inpatient transitions of care pharmacist reduce hospital re-presentations in adult patients discharging home?
Cohort (n=1,605)
Does a dedicated inpatient transitions of care pharmacist reduce hospital re-presentations in adult patients discharging home?
Integrating a dedicated pharmacist into transitions of care significantly reduces hospital re-presentations up to 1 year post-discharge and yields substantial institutional cost savings.
Answers are grounded in this paper and cite their sources.
May support pharmacist-led transitions programs; leaves open causal benefit pending randomized confirmation.
BACKGROUND: Medication management during transitions of care (TOC) impacts clinical outcomes. Published literature on TOC implementation is increasing, but data remains limited regarding the optimal role for the inpatient pharmacist, particularly in the community health setting. OBJECTIVE: To evaluate the impact of a dedicated inpatient TOC pharmacist on re-presentations following discharge. METHODS: This is a prospective study with historical control. All adult patients discharging home from study units were eligible. The TOC pharmacist (1) reviewed medication history and admission reconciliation, (2) met the patient/caregiver to assess barriers, (3) reviewed discharge reconciliation, (4) performed discharge education, and (5) communicated with next level of care. The primary outcome was 30 day re-presentation rate. Secondary outcomes included 60, 90, and 365 day re-presentation rates. IRB approval was obtained. RESULTS: Three hundred and eighty four patients met inclusion criteria. When compared to 1,221 control patients, the intervention had an 11% absolute and 50.2% relative reduction in 30 day re-presentation rate (OR 0.43, 95% CI 0.30-0.61, NNT 9). Reductions in re-presentations at 60, 90 and 365 days remained statistically significant. Utilization avoidance was $786,347. For every $1 invested in pharmacist time, $12 was saved. The TOC pharmacist made a total of 904 interventions (mean 2.4 per patient). CONCLUSION: This study provides new information from previous studies and represents the largest study with significant and sustained reductions in re-presentations. Integrating a pharmacist into an interdisciplinary team for medication management during TOC in a community health system is beneficial for patients and financially favorable for the institution.
No takes yet. Share an insight, caveat, or question.
Rafferty et al. (2016) conducted a cohort in Transitions of care (n=1,605). Dedicated inpatient transitions of care (TOC) pharmacist vs. Historical control was evaluated on 30 day re-presentation rate (OR 0.43, 95% CI 0.30-0.61). A dedicated inpatient transitions of care pharmacist reduced 30-day re-presentation rates compared to historical controls.
Synapse has enriched 10 related papers. Consider them for comparative context: